R. B. Sartor

This study identifies protective and aggressive bacterial subsets and metabolites in PSC patients and mice, showing their impact on hepatobiliary inflammation and fibrosis.

This study shows that BET protein inhibition reduces macrophage inflammation and colitis severity by altering chromatin accessibility and gene expression.

This paper develops FKK6, a non-cytotoxic PXR agonist derived from microbial metabolite mimicry, which reduces inflammation and validates the strategy for drug discovery.

The paper shows that Yersiniabactin-producing AIEC bacteria cause inflammation-associated fibrosis in mice, with Ybt import receptor FyuA influencing fibrosis severity.